Caliper Life Sciences, Inc.
Robbins Umeda LLP Announces an Investigation of Caliper Life Sciences, Inc.
Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of Caliper Life Sciences, Inc. (NASDAQ: CALP) in connection with their efforts to sell the company to PerkinElmer, Inc. (NYSE: PKI)
On September 8, 2011, Caliper announced that it had entered into a definitive merger agreement pursuant to which PerkinElmer will acquire all outstanding shares of the company in an all cash transaction. According to the terms of the deal, shareholders will receive $10.50 for each share of Caliper they own. The transaction is expected to close as soon as the fourth quarter of 2011.
Robbins Umeda LLP’s investigation focuses on whether Caliper’s board is undertaking a fair process to obtain maximum value and adequately compensate shareholders in light of the company’s recent positive financial results. On August 2, 2011, Caliper announced second quarter 2011 financial results that were well above analyst estimates. The company reported an adjusted EPS of $0.02 for the quarter, which exceeded analyst expectations of an EPS loss of $0.02 during the same period. Additionally, Caliper reported $38.34 million in revenue for the quarter, compared to analyst estimates of only $34.40 million for the same period.
Furthermore, Robbins Umeda is investigating whether self-dealing and other employment guarantees played a part in the decision by the board to enter into agreements with PerkinElmer. Upon closure, Kevin Hrusovsky, Caliper’s Chief Executive Officer, is slated to join PerkinElmer’s senior leadership team.
If you own stock in Caliper and would like more information about your shareholder rights, please complete the form below and we will contact you directly. We also welcome you to call us at 800-350-6003.